Xeris Biopharma Holdings, Inc. - Common Stock (XERS)

One of the company's key drugs won't be challenged by a competing medication anytime soon.

Xeris Biopharma (XERS) Q3 2025 Earnings Transcript

Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance.

Let's have a look at the gap up and gap down stocks in today's session.

Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to $280–$290M.

XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score.

XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.

Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS).

The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

XERS stock results show that Xeris Biopharma Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.